Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair

Arghya Paul, Anwarul Hasan, Hamood Al Kindi, Akhilesh K. Gaharwar, Vijayaraghava T S Rao, Mehdi Nikkhah, Su Ryon Shin, Dorothee Krafft, Mehmet R. Dokmeci, Dominique Shum-Tim, Ali Khademhosseini

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

The objective of this study was to develop an injectable and biocompatible hydrogel which can efficiently deliver a nanocomplex of graphene oxide (GO) and vascular endothelial growth factor-165 (VEGF) pro-angiogenic gene for myocardial therapy. For the study, an efficient nonviral gene delivery system using polyethylenimine (PEI) functionalized GO nanosheets (fGO) complexed with DNAVEGF was formulated and incorporated in the low-modulus methacrylated gelatin (GelMA) hydrogel to promote controlled and localized gene therapy. It was hypothesized that the fGOVEGF/GelMA nanocomposite hydrogels can efficiently transfect myocardial tissues and induce favorable therapeutic effects without invoking cytotoxic effects. To evaluate this hypothesis, a rat model with acute myocardial infarction was used, and the therapeutic hydrogels were injected intramyocardially in the peri-infarct regions. The secreted VEGF from in vitro transfected cardiomyocytes demonstrated profound mitotic activities on endothelial cells. A significant increase in myocardial capillary density at the injected peri-infarct region and reduction in scar area were noted in the infarcted hearts with fGOVEGF/GelMA treatment compared to infarcted hearts treated with untreated sham, GelMA and DNAVEGF/GelMA groups. Furthermore, the fGOVEGF/GelMA group showed significantly higher (p < 0.05, n = 7) cardiac performance in echocardiography compared to other groups, 14 days postinjection. In addition, no significant differences were noticed between GO/GelMA and non-GO groups in the serum cytokine levels and quantitative PCR based inflammatory microRNA (miRNA) marker expressions at the injected sites. Collectively, the current findings suggest the feasibility of a combined hydrogel-based gene therapy system for ischemic heart diseases using nonviral hybrid complex of fGO and DNA.

Original languageEnglish (US)
Pages (from-to)8050-8062
Number of pages13
JournalACS Nano
Volume8
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Graphite
Hydrogel
Hydrogels
genes
Oxides
Graphene
delivery
graphene
Repair
Genes
gene therapy
Gene therapy
oxides
Nanosheets
myocardial infarction
heart diseases
Polyethyleneimine
echocardiography
Echocardiography
scars

Keywords

  • gene delivery
  • graphene oxide
  • injectable hydrogel
  • myocardial therapy
  • nanomedicine

ASJC Scopus subject areas

  • Engineering(all)
  • Materials Science(all)
  • Physics and Astronomy(all)

Cite this

Paul, A., Hasan, A., Kindi, H. A., Gaharwar, A. K., Rao, V. T. S., Nikkhah, M., ... Khademhosseini, A. (2014). Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano, 8(8), 8050-8062. https://doi.org/10.1021/nn5020787

Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. / Paul, Arghya; Hasan, Anwarul; Kindi, Hamood Al; Gaharwar, Akhilesh K.; Rao, Vijayaraghava T S; Nikkhah, Mehdi; Shin, Su Ryon; Krafft, Dorothee; Dokmeci, Mehmet R.; Shum-Tim, Dominique; Khademhosseini, Ali.

In: ACS Nano, Vol. 8, No. 8, 2014, p. 8050-8062.

Research output: Contribution to journalArticle

Paul, A, Hasan, A, Kindi, HA, Gaharwar, AK, Rao, VTS, Nikkhah, M, Shin, SR, Krafft, D, Dokmeci, MR, Shum-Tim, D & Khademhosseini, A 2014, 'Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair', ACS Nano, vol. 8, no. 8, pp. 8050-8062. https://doi.org/10.1021/nn5020787
Paul, Arghya ; Hasan, Anwarul ; Kindi, Hamood Al ; Gaharwar, Akhilesh K. ; Rao, Vijayaraghava T S ; Nikkhah, Mehdi ; Shin, Su Ryon ; Krafft, Dorothee ; Dokmeci, Mehmet R. ; Shum-Tim, Dominique ; Khademhosseini, Ali. / Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. In: ACS Nano. 2014 ; Vol. 8, No. 8. pp. 8050-8062.
@article{21ab121aa6e34145a45989fe4d74f941,
title = "Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair",
abstract = "The objective of this study was to develop an injectable and biocompatible hydrogel which can efficiently deliver a nanocomplex of graphene oxide (GO) and vascular endothelial growth factor-165 (VEGF) pro-angiogenic gene for myocardial therapy. For the study, an efficient nonviral gene delivery system using polyethylenimine (PEI) functionalized GO nanosheets (fGO) complexed with DNAVEGF was formulated and incorporated in the low-modulus methacrylated gelatin (GelMA) hydrogel to promote controlled and localized gene therapy. It was hypothesized that the fGOVEGF/GelMA nanocomposite hydrogels can efficiently transfect myocardial tissues and induce favorable therapeutic effects without invoking cytotoxic effects. To evaluate this hypothesis, a rat model with acute myocardial infarction was used, and the therapeutic hydrogels were injected intramyocardially in the peri-infarct regions. The secreted VEGF from in vitro transfected cardiomyocytes demonstrated profound mitotic activities on endothelial cells. A significant increase in myocardial capillary density at the injected peri-infarct region and reduction in scar area were noted in the infarcted hearts with fGOVEGF/GelMA treatment compared to infarcted hearts treated with untreated sham, GelMA and DNAVEGF/GelMA groups. Furthermore, the fGOVEGF/GelMA group showed significantly higher (p < 0.05, n = 7) cardiac performance in echocardiography compared to other groups, 14 days postinjection. In addition, no significant differences were noticed between GO/GelMA and non-GO groups in the serum cytokine levels and quantitative PCR based inflammatory microRNA (miRNA) marker expressions at the injected sites. Collectively, the current findings suggest the feasibility of a combined hydrogel-based gene therapy system for ischemic heart diseases using nonviral hybrid complex of fGO and DNA.",
keywords = "gene delivery, graphene oxide, injectable hydrogel, myocardial therapy, nanomedicine",
author = "Arghya Paul and Anwarul Hasan and Kindi, {Hamood Al} and Gaharwar, {Akhilesh K.} and Rao, {Vijayaraghava T S} and Mehdi Nikkhah and Shin, {Su Ryon} and Dorothee Krafft and Dokmeci, {Mehmet R.} and Dominique Shum-Tim and Ali Khademhosseini",
year = "2014",
doi = "10.1021/nn5020787",
language = "English (US)",
volume = "8",
pages = "8050--8062",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair

AU - Paul, Arghya

AU - Hasan, Anwarul

AU - Kindi, Hamood Al

AU - Gaharwar, Akhilesh K.

AU - Rao, Vijayaraghava T S

AU - Nikkhah, Mehdi

AU - Shin, Su Ryon

AU - Krafft, Dorothee

AU - Dokmeci, Mehmet R.

AU - Shum-Tim, Dominique

AU - Khademhosseini, Ali

PY - 2014

Y1 - 2014

N2 - The objective of this study was to develop an injectable and biocompatible hydrogel which can efficiently deliver a nanocomplex of graphene oxide (GO) and vascular endothelial growth factor-165 (VEGF) pro-angiogenic gene for myocardial therapy. For the study, an efficient nonviral gene delivery system using polyethylenimine (PEI) functionalized GO nanosheets (fGO) complexed with DNAVEGF was formulated and incorporated in the low-modulus methacrylated gelatin (GelMA) hydrogel to promote controlled and localized gene therapy. It was hypothesized that the fGOVEGF/GelMA nanocomposite hydrogels can efficiently transfect myocardial tissues and induce favorable therapeutic effects without invoking cytotoxic effects. To evaluate this hypothesis, a rat model with acute myocardial infarction was used, and the therapeutic hydrogels were injected intramyocardially in the peri-infarct regions. The secreted VEGF from in vitro transfected cardiomyocytes demonstrated profound mitotic activities on endothelial cells. A significant increase in myocardial capillary density at the injected peri-infarct region and reduction in scar area were noted in the infarcted hearts with fGOVEGF/GelMA treatment compared to infarcted hearts treated with untreated sham, GelMA and DNAVEGF/GelMA groups. Furthermore, the fGOVEGF/GelMA group showed significantly higher (p < 0.05, n = 7) cardiac performance in echocardiography compared to other groups, 14 days postinjection. In addition, no significant differences were noticed between GO/GelMA and non-GO groups in the serum cytokine levels and quantitative PCR based inflammatory microRNA (miRNA) marker expressions at the injected sites. Collectively, the current findings suggest the feasibility of a combined hydrogel-based gene therapy system for ischemic heart diseases using nonviral hybrid complex of fGO and DNA.

AB - The objective of this study was to develop an injectable and biocompatible hydrogel which can efficiently deliver a nanocomplex of graphene oxide (GO) and vascular endothelial growth factor-165 (VEGF) pro-angiogenic gene for myocardial therapy. For the study, an efficient nonviral gene delivery system using polyethylenimine (PEI) functionalized GO nanosheets (fGO) complexed with DNAVEGF was formulated and incorporated in the low-modulus methacrylated gelatin (GelMA) hydrogel to promote controlled and localized gene therapy. It was hypothesized that the fGOVEGF/GelMA nanocomposite hydrogels can efficiently transfect myocardial tissues and induce favorable therapeutic effects without invoking cytotoxic effects. To evaluate this hypothesis, a rat model with acute myocardial infarction was used, and the therapeutic hydrogels were injected intramyocardially in the peri-infarct regions. The secreted VEGF from in vitro transfected cardiomyocytes demonstrated profound mitotic activities on endothelial cells. A significant increase in myocardial capillary density at the injected peri-infarct region and reduction in scar area were noted in the infarcted hearts with fGOVEGF/GelMA treatment compared to infarcted hearts treated with untreated sham, GelMA and DNAVEGF/GelMA groups. Furthermore, the fGOVEGF/GelMA group showed significantly higher (p < 0.05, n = 7) cardiac performance in echocardiography compared to other groups, 14 days postinjection. In addition, no significant differences were noticed between GO/GelMA and non-GO groups in the serum cytokine levels and quantitative PCR based inflammatory microRNA (miRNA) marker expressions at the injected sites. Collectively, the current findings suggest the feasibility of a combined hydrogel-based gene therapy system for ischemic heart diseases using nonviral hybrid complex of fGO and DNA.

KW - gene delivery

KW - graphene oxide

KW - injectable hydrogel

KW - myocardial therapy

KW - nanomedicine

UR - http://www.scopus.com/inward/record.url?scp=84906673698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906673698&partnerID=8YFLogxK

U2 - 10.1021/nn5020787

DO - 10.1021/nn5020787

M3 - Article

VL - 8

SP - 8050

EP - 8062

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 8

ER -